Zibotentan
Names | |
---|---|
Preferred IUPAC name
N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide | |
Other names
ZD4054
| |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
ECHA InfoCard
|
100.171.075 |
IUPHAR/BPS |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C19H16N6O4S | |
Molar mass | 424.44 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Zibotentan (
INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca.[1] It is an endothelin receptor antagonist.[2]
Zibotentan was granted
fast track status
for the treatment of prostate cancer by the FDA.
It failed a phase III clinical trial for prostate cancer,[3] but other trials are planned.[4] Tolerability of zibotentan plus docetaxel has been evaluated.[5]
Zibotentan has also been studied in clinical trials for treatment of
non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease,[6] bone metastasis, and heart failure.[7]
References
- ^ James and Growcott (2009). "Drugs of the Future".
- PMID 21414193.
- ^ "AZ's zibotentan flunks late-stage prostate cancer trial - FierceBiotech". www.fiercebiotech.com. Retrieved 16 April 2018.
- ^ "Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures - GEN". GEN. 28 September 2010. Retrieved 16 April 2018.
- S2CID 29707062.
- ^ "A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.
- ^ "Zibotentan - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.